Actively Recruiting
Evaluating Pfizer-BioNTech COVID-19 mRNA Vaccine to Enhance Immunotherapy Response in Stage IV Non-Small Cell Lung Cancer
Led by University of Florida · Updated on 2026-11-02
500
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating whether the Pfizer-BioNTech COVID-19 mRNA vaccine can improve the effectiveness of immune checkpoint inhibitors ICIs in patients with stage IV non-small cell lung cancer NSCLC. Although ICIs have extended survival for many, most patients do not achieve lasting responses. Previous data suggest that COVID mRNA vaccines combined with ICIs may enhance survival and increase PD-L1 expression on tumors. This trial aims to evaluate this combinations impact on treatment outcomes. Participants are randomized to either receive the Pfizer-BioNTech COVID-19 mRNA vaccine within 7 days before starting their planned pembrolizumab and chemotherapy treatment or to begin pembrolizumab and chemotherapy without prior vaccination. Those who decline randomization may join a patient-preference cohort, choosing when to receive the COVID-19 mRNA vaccine relative to their cancer therapy. The vaccine is obtained at local pharmacies and is expected to be the most current available. During the study, participants will be monitored for immune-related adverse events requiring hospitalization within 60 days of starting pembrolizumab and chemotherapy. Researchers will also assess progression-free survival over five years and changes in tumor PD-L1 expression after vaccination. The feasibility of administering the COVID-19 vaccine shortly before immunotherapy will be evaluated. Overall participation may last several years, with ongoing safety and effectiveness assessments.
CONDITIONS
Brief Title
Universal Immunization to Fortify Immunotherapy Efficacy and Response
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here